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apy (ART) for the prevention and treatment of HIV infection has been
one of the greatest medical advancements in the past few decades.
When those without HIV use ART appropriately as either pre-
exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), HIV
acquisition is almost universally prevented (Grant et al., 2010). Similar-
ly, when those with HIV use therapy appropriately, transmission to
others rarely if ever occurs (Cohen et al., 2011), and the risk of develop-
ing AIDS is completely eliminated.
There are over 35million people living with HIV, and manymillions
more at risk for acquisition. Most live in resource poor regions. Deliver-
ing these expensive drugs to those in need, and getting people to adhere
to complex regimens indeﬁnitely, is a daunting challenge. Without un-
precedented investments in global health and implementation science,
it is unclear if ART alone will ultimately eliminate the epidemic.
The HIV research agenda has therefore shifted. Themain biomedical
goals for discovery and translational science are to develop an effective
vaccine for those at risk for HIV and to develop a safe, scalable, short-
term intervention that results in durable remission for those with HIV
(in others words, a “cure”). Although the prevention and treatment re-
search agendas are often competing for dwindling research dollars, the
reality is that in the past few years these agendas have begun to merge.
The distinction between prevention and a cure is now surprisingly hard
to deﬁne, and many of the most exciting advances in vaccine research
are now being actively repurposed for cure research.
We and others have commented on the PreP-PEP-cure continuum
(Barouch & Deeks, 2014). When HIV infects activated CD4+ T cells,
HIV DNA encoding replication-competent virus is successfully integrat-
ed into the host cell genome. Most of these cells die rapidly, but rare
cells may survive and return to a resting state that is non-permissive
for HIV gene expression. These cells persist as long lived memory
CD4+ T cells (the “latent reservoir”), preventing cure by ART
(Siliciano et al., 2003). If ART after infection blocks the establishment
of a latent reservoir, and the infection eventually cleared, is that PEP
or a cure? This is more than a theoretical debate, as is illustrated by
the well-publicized “Mississippi Baby” case (Persaud et al., 2013). ART
given at hour 31 of life to an infant who was clearly infected nearly
prevented establishment of a latent reservoir, as evidence by the fact
she had no viral rebound 18 months later when therapy was stopped.
Unfortunately, this preventionwas not complete, as the child eventually
exhibited viral rebound after more than two years off therapy. Never-⁎ Corresponding author.
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vent the establishment of latent infection.
Decades of investment in HIV vaccine efforts have led to a number of
breakthroughs that are reshaping the prevention and cure agendas.
Louis Picker and his team have repurposed cytomegalovirus (CMV) as
a live vector to deliver SIV (and soon HIV) peptides to the immune sys-
tem, resulting in the durable generation of polyclonal virus-speciﬁc
CD8+ effector memory T cells. Although this vaccine does not prevent
acquisition of SIV in macaques, some infected animals clearly eliminate
infection soon after acquisition (Hansen et al., 2013). One likely expla-
nation is that the pre-existing vaccine induced CD8+ T cell response
eliminated infected cells before they could revert back to a resting
state and establish latency. These experiments—which as of now have
been limited to non-human primatemodels—provide theﬁrst deﬁnitive
proof that established SIV (and, by extension—HIV) infection may be
curable. Although the ﬁrst series of studies in humans will likely focus
on the role of CMV vector-based vaccines as prevention for HIV-
uninfected individuals, it is expected that this approach will rapidly be
studied in a curative setting.
The encouraging results from the RV144 vaccine study suggest that
envelope-speciﬁc antibodies can prevent HIV acquisition (Haynes
et al., 2012). Detailed studies of those with HIV have led to the identiﬁ-
cation of a growing number of antibodies that are potent and broadly
neutralizing. While the prevention ﬁeld is struggling with the daunting
challenge of identifying an immunogen strategy to generate these
complex antibodies in uninfected persons, those interested in cure
are rapidly repurposing these broadly neutralizing antibodies as poten-
tial therapies. Theoretically, such antibodies can be engineered to recog-
nize and clear infected cells perhaps by stimulating antibody-
dependent cell-mediated cytotoxicity (Barouch et al., 2013). This ap-
proach, when preceded by interventions that reactivate latent HIV,
could be an important addition to cure strategies, particularly since
existing CTL responses in patients on ART are unlikely to be sufﬁcient
(Shan et al., 2012).
Funds for biomedical research are plummeting. This can force disci-
plines to compete aggressively for those funds, or ﬁndways to work to-
gether. The natural overlap between prevention and treatment agendas
in the HIV arena has led to a number of highly productive cross-
disciplinary collaborations, and a palpable sense that research in the fu-
ture will be more collaborative. Major investments into team science
and the development of large, multi-institute “collaboratories” that en-
courage experts from prevention and treatment to work together couldthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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will never be able to address.
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